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Abstract
For settings with a binary treatment and a binary outcome, instrumental
variables can be used to construct bounds on a causal treatment effect. With
continuous outcomes, meaningful bounds are more difficult to obtain because
the domain of the outcome is typically unrestricted. In this paper, we combine
an instrumental variable and subjective assumptions in the context of an obser-
vational cohort study of HIV-infected women to construct meaningful bounds
on the initial-stage causal effect of antiretroviral therapy on CD4 count. The
subjective assumptions are encoded in terms of the potential outcomes that are
identified by observed data as well as a sensitivity parameter that captures the
impact of unmeasured confounding. Measured confounding is adjusted using the
method of inverse probability weighting (IPW). With extra information from an
IV, we quantify both the causal treatment effect and the degree of the unmea-
sured confounding. We demonstrate our method by analyzing data from the HIV
Epidemiology Research Study.
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1 Introduction
Observational studies offer an important alternative to randomized clinical trials when
assigning a treatment to study subjects is unethical or practically impossible (Rosenbaum
2002). However analyzing data from such studies often confronts the difficulty that
a direct comparison between the treated and untreated subjects does not necessarily
show the causal effect of the treatment due to confounding. Informally, confound-
ing is caused by factors that have causal effects on both treatment and outcome (see
VanderWeele and Shpitser 2011, for more rigorous discussions and definitions of con-
founding and confounders). To adjust for the confounding effect, observational studies
typically include collecting a set of covariates with the hope that most confounders if
not all are measured. Statistical methods for controlling for the confounding effect un-
der the assumption of no unmeasured confounding include multivariate adjustment via
regression models, propensity score risk adjustment, propensity score matching, and
inverse probability weighting (IPW) (Bang and Robins 2005; Kang and Schafer 2007;
Robins et al. 1994; Rosenbaum and Rubin 1984; Hogan and Lancaster 2004; D’Agostino
1998; Robins et al. 2000, among others).
The assumption of no unmeasured confounding is untestable in general and very
often implausible. In this case, making causal inference on the treatment effect as well
as obtaining a quantitative measure about the degree of unmeasured confounding is
imperative. The two objectives are generally not achievable in a single observational
study, but possible given the existence of an instrumental variable (IV).
The IV methods can be traced back to 1920’s (Stock and Trebbi 2003; Wright
1928), and have been extensively implemented in econometric and recent bio-medical
research. Loosely speaking, an IV can be envisioned as a ‘randomizer’ which varies
exogenously, has a causal effect on treatment received, but has no causal effect on the
outcome except through treatment. By convention, these three conditions are referred
to as the exogeneity, monotonicity, and exclusion restriction assumptions, respectively
(Angrist et al. 1996). When a valid IV exists, it can be used to draw inference about the
causal treatment effect, despite the existence of unmeasured confounding. However, the
IV estimate of the treatment effect applies only to a specific non-identifiable subpopula-
tion unless additional assumptions are made (Angrist et al. 1996; Imbens and Angrist
1994). In simple settings with a binary treatment and a binary outcome, IV methods
also can be used to construct bounds on a population causal treatment effect (Robins
1989; Manski 1990; Joffe 2001; Cheng and Small 2006; Zhang and Rubin 2003), where
the uncertainty of the impact of unmeasured confounding is accounted for by a bound
(in contrast to a point) estimate. With continuous outcomes, meaningful bounds are
not straightforward to obtain because the domain of the outcome is typically unre-
stricted.
In this paper, we consider the case of having an observational study with a continu-
ous outcome and a valid IV. We propose to combine the IV and subjective assumptions,
in the context of the HIV Epidemiology Research Study (HERS) (Smith et al. 1997),
to construct meaningful bounds on (1) the population average treatment effect (ATE)
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and (2) the degree of unmeasured confounding. The HERS was conducted when the
highly active antiretroviral therapy (HAART) first became available to HIV-infected
patients but was not randomly assigned. Of particular interest was the initial-stage
causal effect of HAART on patient’s CD4+ T lymphocytes (CD4) count, an important
immunological marker for immune system function and disease stage. The study was
conducted at two types of study site, community clinics and academic health centers,
which we use as an IV. The study had collected an extensive set of covariates which
can be used to adjust for part of the confounding effect, but unmeasured confounding
may still exist and the magnitude of its impact is unclear. To have a sense of its im-
pact, many HIV-positive individuals in the early HAART era were reluctant to initiate
therapy due to fear of adverse side effects and toxicity. At the same time, physicians
tended to prescribe HAART to patients with poor health condition, particularly with
low CD4 count. These confounding factors were not fully measured and could possibly
confound the HAART effect in a non-negligible way.
To account for the measured confounding effect, we implement the inverse proba-
bility weighting method proposed by Robins et al. (1994), assuming that each subject
has a probability between 0 and 1 to receive HAART. In the ideal case when unmea-
sured confounding is absent, the IPW method can consistently estimate the ATE, and
can be augmented to achieve double robustness (see Bang and Robins 2005). With
unmeasured confounding, we adopt the method of Robins et al. (1999) and incorpo-
rate a sensitivity parameter into the IPW estimating equations to capture the effect
of unmeasured confounding. The sensitivity parameter, defined as the systematic dif-
ference between the treated and untreated patients if hypothetically having these pa-
tients exposed to the same treatment condition, provides a measure of the magnitude
of unmeasured confounding. Without external information, however, the sensitivity
parameter is not identified by observed data. So in practice, this parameter is often
used to conduct a sensitivity analyses to assess the robustness of the estimated causal
treatment effect (Ko et al. 2003; Brumback et al. 2004) to unmeasured confounding.
In this paper, differential HAART prescription rates at the two types of study site
(study site used as an IV) provide an extra piece of information that indeed allows us
to infer the magnitude of the sensitivity parameter. In this paper, we impose a set
of subjective assumptions in the context of the HERS. These subjective assumptions
are encoded in terms of the potential outcomes as well as a sensitivity parameter for
unmeasured confounding. Putting together the sensitivity parameter, the IPW esti-
mating equations to account for measured confounding, and the IV estimating equation
leads to a system of estimating equations, unified under a constraint imposed by the
principal stratification (Frangakis and Rubin 2002). By solving the unified equations,
we achieve our two objectives to (1) estimate the population average treatment effect of
HAART at the initial treatment stage and (2) quantify the magnitude of unmeasured
confounding.
The rest of the paper is organized as follows: More details about the HERS are
provided in Section 2. Notations and models are given in Section 3. In Section 4,
we review the IV method and the IPW method, and introduce a unified system of
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estimating equations based on them. In Section 5, we present a set of contextually
plausible constraints and assumptions and develop bounds on the average treatment
effect of HAART on CD4 count and on the degree of unmeasured confounding. In
Section 6, we analyze the HERS data, and finally in Section 7, we offer some points
for discussion.
2 Motivating Example: HERS
The HERS was conducted from 1993-2001 to investigate the natural history of HIV
progression in women. Details of the HERS have been reported in Smith et al. (1997).
In the study, a total of 871 HIV-infected women were enrolled at four study sites:
Baltimore, New York City, Detroit, and Providence. The first two sites were community
clinics while the other two were academic medical centers. Clinical outcomes such as
CD4 count were recorded about every six months since enrollment. Starting from
1996, HAART became the recommended treatment regimen for HIV infected people,
especially for those with low CD4 counts (Carpenter et al. 2000). Our analyses use data
extracted from 201 women at their 8th visit, who 6 months previously were HAART-
naive and had low CD4 counts (< 350 cells/mm3). Using the HERS data, we want to
estimate the initial-stage causal effect of HAART on CD4 count among this population.
The study had collected a rich set of covariates, but unmeasured confounding might
still exist.
The characteristics of the 201 women are summarized in Table 1. Among them,
46 (23%) have initiated the HAART. Those receiving HAART have a higher CD4
count on average than those not on HAART, but this “as-received” treatment effect
(Ten Have et al. 2008) is not statistically significant (standard normal z statistic =
0.58). Ko et al. (2003) analyzed the data from the HERS and screened out several
candidate confounders, which we list in the upper panel of Table 1. In brief, patients
receiving HAART are more likely to be aware their HIV status and on HAART at
enrollment and at the previous visit; less likely to show any HIV symptom and be a
drug user; have higher viral loads (HIV-RNA) at enrollment and at the previous visit;
and consist of relatively more white and less black.
In this paper, the type of study site is used as an IV assuming that conventional
IV assumptions (outlined in Section 3.1) are satisfied. The validity of making these
assumptions will be discussed in Section 7. In the lower panel of Table 1, we summarize
the patient’s CD4 count and HAART receipt rates stratified by the type of study site.
Notably, patients at academic centers are more likely to be prescribed HAART (28
versus 18%) than those at the community clinics, and their average CD4 count is
slightly higher. With the exogeneity assumption, this difference in CD4 count is the
causal effect of study site. Further with the exclusion restriction, it is the causal effect
of the differential HAART assignment between the two types of study sites. In the
following, we will explore using this extra piece of information in conjunction with
other assumptions to infer the causal effect of HAART and unmeasured confounding.
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Table 1: Summary of patient demographic characteristics by HAART receipt status
and study site. The numbers inside parentheses are standard errors. z stands for
a standard normal test for comparing two sample means, and χ22 for a chi-squared
statistic for Pearson’s chi-squared test.
Received HAART? Comparison
Yes No statistic
Number of patients, n 46 155 -
Average CD4 counts, cell/mm3 229 (19) 216 (11) z = 0.58
Candidate confounders
Race:
black; white; others 46; 28; 26% 61; 15; 24% χ22 = 5.1
ART receipt rate
at enrollment, % 50% (7.4) 39% (3.9) z = 1.2
at previous visit, % 74% (6.5) 57% (4.0) z = 1.9
Presence of HIV symptom, % 26% (6.5) 37% (3.9) z = 1.2
HIV RNA, log10 copy/mm
3
at enrollment, average 3.2 (.15) 3.1 (.07) z = .78
at previous visit, average 3.7 (.15) 3.4 (.09) z = 1.5
Intravenous drug use
recent, % 22% (6.1) .25 (.035) z = .19
lifetime, % 61% (7.2) .63 (.039) z = .04
Aware of HIV status % 83% (5.6) .81 (.032) z = .08
The HERS study site
Academic centers Community clinics
Number of patients, n 93 108 -
HAART received, n; % 26; 28% 20; 18% z = 1.4
Average CD4, cell/mm3 230 (14) 210 (12) z = 1.0
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3 Notations and Definitions
3.1 Notations
We use Z to denote the IV (in the HERS, Z = 1 if the study site is an academic medical
center and = 0 otherwise), and Az the potential treatment status that an individual
would receive should Z be set to z. Hence, each individual has a pair of potential
treatments (A1, A0) that she would potentially receive at the two types of study site.
The actual treatment received is A = AZ = A1Z+A0(1−Z), where A = 1 means that
the individual receives HAART, and 0 otherwise. With the Stable Unit Treatment
Value Assumption (Rubin 1974), we use Yz(a) to denote the potential outcome for an
individual should we hypothetically set the IV to z and her treatment to a. Thus, the
actual outcome observed is Y = YZ(A) = YZ(AZ). Further, we denote all confounders
by a vector X , and the measured confounders by V , a subvector of X . The observed
data consist of n identically and independently distributed copies of {Xi, Zi, Ai, Yi},
i = 1, 2, . . . , n.
We assume that the conventional IV assumptions – the exogeneity, exclusion restric-
tion, and monotonicity assumptions (Angrist et al. 1996; Imbens and Angrist 1994) –
are satisfied. The exclusion restriction assumes Y (a) ≡ Y1(a) = Y0(a), i.e. the IV
has no direct effect on the outcome beyond its impact on individual’s treatment. The
monotonicity assumption requires Pr(A1 ≥ A0) = 1, i.e. an individual who would not
receive HAART at an academic medical center would not do so at a community clinic
either. The exogeneity assumes that Z is jointly independent of the potential outcomes
and treatments, Z ⊥ (A0, A1, Y (0), Y (1)).
3.2 Definitions of Causal Treatment Effect
The causal effect of HAART treatment can be defined at different levels. The average
treatment effect (ATE), E{Y (1) − Y (0)}, is defined over the entire population. The
ATE is of broad interest in public health and epidemiology, and is the parameter
of interest in this paper. With an IV, the local average treatment effect (LATE;
Imbens and Angrist 1994), E{Y (1)− Y (0) | A0 = 0, A1 = 1}, is defined as the average
treatment effect among a subpopulation who would receive the treatment only when
Z = 1. The LATE can be estimated given a valid IV, not subject to the presence
of unmeasured confounding. However, the facts that this subpopulation is not fully
identifiable and the interpretation of the LATE depends on the choice of IV pose
a significant limitation for generalizing results to a broader population and to other
settings.
The relationship between the ATE and LATE can be expressed using the princi-
pal stratification (Frangakis and Rubin 2002). For a binary instrument and a binary
treatment, the principal stratification suggests that the population can be partitioned
into four mutually exclusive subpopulations based on the potential treatments each
individual would have. In our case, the potential treatments have the following four
possible combinations, (A0, A1) ∈ {(0, 0), (0, 1), (1, 0), (1, 1)}, where {(A0, A1) = (0, 0)}
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indicates the subpopulation who would never receive the HAART; {(A0, A1) = (0, 1)}
is the subpopulation who would receive HAART only at academic medical centers; and
so forth. The monotonicity assumption, Pr(A1 ≥ A0) = 1, implies that the subpopu-
lation {(A0, A1) = (1, 0)} is an empty set. Henceforth, we denote the remaining three
subpopulations by Pjk = {A0 = j, A1 = k}, j ≤ k.
We denote the ATE and LATE by βATE and βLATE, respectively. Then their rela-
tionship can be expressed by
βATE = π01β
LATE + π00{µ00(1)− µ00(0)}+ π11{µ11(1)− µ11(0)}. (1)
where πjk = Pr(Pjk) and µjk(a) = E{Y (a) | Pjk}. In this paper, this relationship is
used to unify the IPW and IV estimation methods, and based on that, a system of
estimating equations is developed to draw inference on the ATE of HAART as well as
the magnitude of unmeasured confounding.
4 Review of Estimation Methods
We review the IPW and IV methods in this section.
4.1 The IPW Method
Putting aside the covariates for the moment, the potential outcomes can be expressed
by a marginal structural mean model (Gange et al. 2007; Robins 1999; Robins et al.
2000)
E[Y (a)] = β0 + β
ATEa, a = 0, 1. (2)
Assuming that Y (a) ⊥ A|V , i.e. unmeasured confounding is absent, we can estimate
βATE by the solution βˆIPW to the IPW estimating equations
U1(βIPW) :=
n∑
i=1
(1, Ai)
⊤W1i(Yi − β1 −AiβIPW) = 0,
where W1i = Ai/e(Vi; γ) + (1− Ai)/{1− e(Vi; γ)}, and e(V ; γ) = Pr(A = 1|V ) is the
propensity score (Rosenbaum and Rubin 1983) with a l-dimension parameter γ. We
assume that 0 < e(V ; γ) < 1.
The IPW method has several properties that are worth mentioning. The efficiency
of the resulting estimator can be improved by using stabilized weights to replace W1i
(Miguel et al. 2001). The estimator can be augmented to achieve double robustness if
we further specify an outcome regression model on Y (Bang and Robins 2005). More-
over, if γ is unknown, βˆIPW remains consistent when γ is replaced by a consistent
estimator γˆ that solves
U2(γ) :=
n∑
i=1
W2i{Ai − e(Vi; γ)} = 0.
where W2i is an appropriate weight function; e.g. W2i = ∂e(Vi; γ)/∂γ in logistic regres-
sions.
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When unmeasured confounding exists, U1(βIPW) is biased, i.e. E{U1(βIPW)} 6= 0.
In this case, Robins (1999) proposed to introduce a sensitivity parameter τ and then
estimate βATE by the solution βˆMIPW(τ) to the following modified IPW estimating
equations
U3(βMIPW, τ) :=
n∑
i=1
(1, Ai)
⊤W1i{Y
∗
i − β2 − AiβMIPW} = 0
where Y ∗i = Yi− τ{Ai− e(Vi; γ)} is the “outcome” corrected for the selection bias due
to unmeasured confounding. For a binary treatment as in this paper, the sensitivity
parameter can be defined as the contrast of the potential outcomes between the treated
and untreated conditional on V .
τ = (a− a′) [E{Y (a)|A = a, V } − E{Y (a)|A = a′, V }]
with a = 1 − a′. In the context of the HERS, τ > 0 means that the HAART is
preferentially given to those with higher CD4 counterfactuals Y (a); τ < 0 means the
opposite is true; and when τ = 0, no unmeasured confounding is implied and the
resulting estimator βˆMIPW(0) = βˆIPW.
Without additional information from data, the parameter τ is not identified. Hence,
the resulting estimator βˆMIPW(τ) is typically used to conduct a sensitivity analysis.
That is, estimate βATE using βˆMIPW(τ) as if τ is known, and then examine the sensi-
tivity of βˆMIPW(τ) by varying the value of τ over its plausible range (Ko et al. 2003;
Brumback et al. 2004).
With an IV and information extracted by IV, it becomes possible to draw inference
about the ATE as well as τ which quantifies the degree of unmeasured confounding.
4.2 The IV Method
The IV methods have been widely used in econometric research (c.f. Wooldrige 2002).
In our just-identified case with a single binary IV and a binary treatment, the standard
IV estimating equations are
U4(βIV) :=
n∑
i=1
(1, Zi)
⊤(Yi − β3 − βIVAi) = 0.
Under the IV assumptions and Cov(Z,A) 6= 0, the solution
βˆIV =
Y Z/Z¯ − Y (1− Z)/(1− Z)
AZ/Z¯ −A(1− Z)/(1− Z)
(3)
is consistent for βLATE (Imbens and Angrist 1994; Angrist et al. 1996; Hernan and Robins
2006). The bars in (3) calculate sample averages, e.g. Y Z =
∑
i YiZi/n. One impor-
tant property of the IV method is that βˆIV remains consistent despite of the existence
of unmeasured confounding.
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Under the framework of the generalized method of moments, the IV estimating
equations are solved using the two-stage least squares method (Angrist and Imbens
1995), and can further incorporate a weight matrix to allow for heteroskedastic or
correlated residuals. The IV methods also can be generalized to deal with multiple IVs
and non-continuous outcomes (c.f. Wooldrige 2002).
5 A Unified System of Estimating Equations
With a set of covariates and an IV in the HERS, we propose to combine the IV and
IPW methods, and develop a unified system of estimation equations as follows,
(U2(γ), U3(βMIPW, τ), U4(βIV))
⊤ = 0, (4)
with a constraint of (1). Note that in (1), parameters µ11(0) and µ00(1) are the averages
of unobserved potential outcomes and not identified. All other parameters are identified
because π11 = E(A = 1|Z = 0), π00 = E(A = 0|Z = 1), π01 = 1 − π00 − π11,
µ11(1) = E(Y |A = 1, Z = 0), and µ00(0) = E(Y |A = 0, Z = 1) (Angrist et al. 1996, and
Rejoinder). When natural limits exist on µ11(0) and µ00(1) e.g. with binary outcomes,
both the ATE and τ are partially identified to bounds. When no natural limits exist
as is our case with continuous outcomes, additional prior information is needed to
implement the constrained estimating equations system, which we will discuss next.
We present three sets of assumptions in the context of the HERS. Each allows us to
identify bounds on the ATE and unmeasured confounding parameter τ . In Sections 5.1
- 5.3, we assume that the sample size n is sufficiently large such that the sampling
variations of the estimating equations (4) is ignored. In Section 5.4 and 5.5, we discuss
inferences on the sampling uncertainty of bound estimates for a finite n.
5.1 Assumption on the Upper Limits of µ11(0) and µ00(1)
The outcome variable of our interest is CD4 count, so both µ00(1) and µ11(0) must be
greater than zero. In our first set of assumptions, we make a simple assumption that
there exist two upper bounds that
Assumption (A): 0 ≤ µ00(1) ≤ ξ1, 0 ≤ µ11(0) ≤ ξ0, with known ξ0 and ξ1.
Assumption (A) leads to a simplified version of the Robins-Manski type bound on
the ATE (Robins 1989; Manski 1990; Zhang and Rubin 2003). It is straightforward to
show that the ATE falls within the interval
[b(ξ0, 0), b(0, ξ1)],
where to emphasize the unidentifiable parameters in (1), we define b(µ11(0), µ00(1)) =
π01 × LATE + π11{µ11(1)− µ11(0)}+ π00{µ00(1)− µ00(0)}.
Then the bound on τ can be inferred by finding the values of τ such that the
corresponding solutions to βˆMIPW(τ) are consistent with the above bound on ATE. For
a given βATE, the solution to U3(βMIPW, τ) = 0 for τ is
τˆn(β
ATE, γ) =
W1A ∗W1(Y − βATEA)− W¯1 ∗W1A(Y − βATEA)
W1A ∗W1(A− e(V ; γ))− W¯1 ∗W1A(A− e(V ; γ))
.
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It is straightforward to verify that τˆn(β
ATE, γ) is a non-increasing function of βATE, so
the unmeasured confounding parameter τ is bounded by
[τ(b(0, ξ1), γ), τ(b(ξ0, 0), γ)],
where τ(βATE, γ) ≡ τˆ∞(β
ATE, γ).
5.2 Constraint on Relationships between µ11(0) and µ00(1) and
Identified Quantities
Assumption (A) alone is sufficient for identifying the bounds on ATE and τ , but in
practice the two upper limits need to sufficiently large and the resulting bounds can
be wide. In the following, we consider making assumptions on the relative magnitude
between the unidentifiable and identifiable quantities.
Assumption (B): We assume that
1. The average treatment effect among P11 is no less than a known δ11,
E{Y (1)− Y (0)|P11} = µ11(1)− µ11(0) ≥ δ11.
A plausible choice for δ11 is zero, that is, we assume that on average, P11 who
would always receive HAART can on average benefit from HAART. We make
this assumption because although suffering from confounding bias, the efficacy of
HAART on the treated patients has been demonstrated by several contemporary
studies. Further, we impose a known lower bound on the average treatment effect
among P00 that
E{Y (1)− Y (0)|P00} = µ00(1)− µ00(0) ≥ δ00.
A negative value of δ00 implies that HAART can be harmful for those who would
never receive HAART at either site. Setting δ00 = 0 implies that HAART is also
beneficial for them on average.
2. The difference on E{Y (0)} between P11 and P00 is bounded above,
E{Y (0)|P11} − E{Y (0)|P00} = µ11(0)− µ00(0) ≤ δy0.
We can set δy0 = 0 by our intuition that in the untreated condition, people who
would always receive HAART have higher degree of HIV progression (lower CD4
on average, compared to those who would never receive HAART).
3. The difference of treatment effects between those who would always receive
HAART and those who would never receive HAART is bounded below,
E{Y (1)−Y (0)|P11}−E{Y (1)−Y (0)|P00} = {µ11(1)−µ11(0)}−{µ00(1)−µ00(0)} ≥ δtrt.
For example, letting δtrt = 0 implies that the treatment effect on those who would
always receive HAART is greater than those would never do so.
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Under this set of assumptions, we show that the ATE is bounded by
[b(c0, µ00(0) + δ00), b(0, c1)]
and τ by
[τ(b(0, c1), γ), τ(b(c0, µ00(0) + δ00), γ)],
where c0 = min{µ11(1)− δ11, µ00(0) + δy0} and c1 = µ11(1) + µ00(0)− δtrt.
5.3 Constraint Conditional on Measured Covariates
For the HERS, it may be more realistic to assume that Assumption (B) holds condi-
tional on clinically important covariates V . So we propose our third set of assumptions
as
Assumption (B’):
1. E{Y (1)− Y (0)|P11, V } ≥ δ11; E{Y (1)− Y (0)|P00, V } ≥ δ00.
2. E{Y (0)|P11, V } − E{Y (0)|P00, V } ≤ δy0.
3. E{Y (1) − Y (0)|P11, V } − E{Y (1) − Y (0)|P00, V } ≥ δtrt, for known δ11, δ00, δy0
and δtrt.
4. Further, we assume that the monotonicity and exclusion restriction assumptions
hold conditional on V , and the constraint (1) becomes
β = π ∗ βLATE +
ˆ
V
E{Y (1)− Y (0)|P11, V }P (P11|V )dF (V )
+
ˆ
V
E{Y (1)− Y (0)|P00, V }P (P00|V )dF (V ), (5)
where V is the support of V with a distribution F (V ). We write the product
π01 ∗ β
LATE as before because both the LATE and π01 are identified by the data.
Again, no observed data are available for E{Y (0)|P11, V } and E{Y (1)|P00, V },
which are denoted by µ11(0, V ) and µ00(1, V ), respectively.
Under (B’) and (5), we obtain a bound on ATE
[π01 × LATE +
ˆ
V
bV (c0(V ), c2(V ))dF, π01 × LATE +
ˆ
V
bV (0, c1(V ))dF ]
and a bound on τ
[τ(π01 × LATE +
ˆ
V
bV (0, c1(V ))dF, γ), τ(π01 × LATE +
ˆ
V
bV (c0(V ), c2(V ))dF, γ)],
where bV (µ11(0, V ), µ00(1, V )) = [E{Y (1)|P11, V }−µ11(0, V )] Pr(P11|V ) + [µ00(1, V )−
E{Y (0)|P00, V }] Pr(P00|V ), c0(V ) = min(E{Y (1)|P11, V }− δ11,E{Y (0)|P00, V }+ δy0),
c1(V ) = E{Y (1)|P11, V }+ E{Y (0)|P00, V } − δtrt, and c2(V ) = E{Y (0)|P00, V }+ δ00.
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5.4 Inference from Finite Samples
To implement (1), we can assume two regression models E(A|Z) = logit−1(η(Z; θ1))
and E(Y |A,Z) = κ(A,Z; θ2) for some known functions η(Z; θ1) and κ(A,Z; θ2). For
binary Z and A, we use two saturated models and specify that η(Z; θ1) = θ10+θ11Z and
κ(A,Z; θ2) = θ20+θ21Z+θ23A+θ23AZ with θ1 = (θ10, θ11)
⊤ and θ2 = (θ20, θ21, θ22, θ23)
⊤.
Here, a saturated additive model for κ(A,Z; θ2) is compatible with the structural model
(2), since one can show that (2) suggests that E(Y |A,Z) is linear in A, Z, and AZ.
Given two regression models, we can obtain consistent estimators θˆ1 and θˆ2 by
solving
U5(θ1, θ2) :=
( ∑n
i=1W3i[Ai − logit
−1{η(Zi; θ1)}]∑n
i=1W4i{Yi − κ(A,Z; θ2)}
)
= 0,
where W3i = ∂logit
−1{η(Zi; θ1)}/∂θ1 and W4i = (1, Zi, Ai, AiZi)
⊤. Then, we esti-
mate πˆ11 = logit
−1{η(0; θˆ1)}, πˆ00 = 1 − logit
−1{η(1; θˆ1)}, πˆ01 = logit
−1{η(1; θˆ1)} −
logit−1{η(0; θˆ1)}, µˆ11(1) = κ(1, 0; θˆ2), and µˆ00(0) = κ(0, 1; θˆ2).
For Assumptions (A) and (B), the function b() can be estimated by replacing
those identifiable quantities with their consistent estimators, i.e. bˆ(µ11(0), µ00(1)) =
πˆ01βˆIV + πˆ11{µˆ11(1) − µ11(0)} + πˆ00{µ00(1) − µˆ00(0)}. Further, we estimate c0 by
cˆ0(δ11, δy0) = min{(µˆ11(1)−δ11), (µˆ00(0)+δy0)} and c1 by cˆ1(δtrt) = µˆ11(1)+µˆ00(0)−δtrt.
By substituting these estimates for their estimands in the bounds, we obtain bound
estimates on the ATE and τ . The results are summarized in Table 2.
To estimate the bounds on ATE and τ under Assumption (B’), we proceed as
follows:
Step 1. We assume two observed-data models conditional on V , E(A|Z, V ) = logit−1(η(Z, V ; θ3)),
and E(Y |Z,A, V ) = κ(Z,A, V ; θ4) for known η(Z, V ; θ3) and κ(Z,A, V ; θ4). For
example, we can assume two linear models without interaction that η(Z, V ; θ3) =
θ30 + θ31Z + θ32V with θ3 = (θ30, θ31, θ
⊤
32)
⊤ and κ(Z,A, V ; θ4) = θ40 + θ41Z +
θ42A+ θ
⊤
43V with θ4 = (θ40, θ41, θ42, θ
⊤
43)
⊤. Let θˆ4 and θˆ3 denote the estimators of
θ4 and θ3 by solving the corresponding estimating equations.
Step 2. With the monotonicity assumption and exclusion restriction conditional on V ,
we estimate that Ê{Y (0)|P00, V } = Ê(Y |Z = 1, A = 0, V = V ) = µ(1, 0, V ; θˆ4),
Ê{Y (1)|P11, V } = µ(0, 1, V ; θˆ4), P̂r(P11|V ) = π(0, V ; θˆ3), and P̂r(P00|V ) = 1 −
π(1, V ; θˆ3). Then we estimate the functions bˆV (), cˆ0(), cˆ1(), and cˆ2() by bringing
in the above estimators.
Step 3. We estimate the distribution F (V ) by the empirical cumulative density function
of V and integrals by empirical sums, e.g. estimate
´
V
bV (c0(V ), c2(V ))dF by∑n
i=1 bˆV (cˆ0(Vi), cˆ2(Vi))/n. Then, we substitute the parameters in (5) by their
estimates.
The resulting bound estimates on the ATE and τ are summarized in Table 2.
12
5.5 Uncertainty Region for Estimated Bounds
An interval that provides (1 − θ)100% coverage probability on a bound estimate is
often called the (1 − θ)100% Uncertainty Region (UR) to distinguish it from a con-
fidence interval. A UR takes into account both the sampling variability and partial
identifiability. Two types of URs are considered in this paper, point-wise and strong
(1− θ)100% coverage URs.
A point-wise UR (Lˆ, Uˆ) contains any particular value ̺ ∈ (L, U) with a probability
of at least (1− θ), where (L, U) denotes the true bound and ̺ is the parameter gener-
ating the data. If the Lˆ and Uˆ are consistent estimates and asymptotically normally
distributed (CAN), a (1− θ)100% point-wise UR is given by
URP-CAN = [Lˆ− c
∗se(Lˆ), Uˆ + c∗se(Uˆ)],
where se(·) is the standard error and c∗ is a critical value. When U − L is large
compared to se(Lˆ) and se(Uˆ), c∗ can be approximated by Φ−1(1 − θ) where Φ is the
normal cumulative density function (Vansteelandt et al. 2006).
A strong UR is defined as an interval that contains the entire set (L, U) with a
probability of at least (1 − θ) (Horowitz and Manski 2000; Vansteelandt et al. 2006).
If both Lˆ and Uˆ are CAN, a strong (1− θ)100% UR is
URS-CAN = [Lˆ− c se(Lˆ), Uˆ + c se(Uˆ)],
with c = Φ−1(1 − θ/2) = 1.96. Without assuming Lˆ and Uˆ to be CAN, a strong
(1 − θ) UR can be obtained using the bootstrap method. Specifically, let (L˜∗, U˜∗)
denote the estimated bound from a bootstrapped sample. A bootstrap strong 95% UR
is the interval (L∗, U∗) satisfying Pr∗(L∗ ≤ L˜∗, U˜∗ ≤ U∗) = 1 − θ and Pr∗(L˜∗ < L∗) =
Pr∗(U˜∗ > U∗), where Pr∗ is the probability measure induced by the bootstrapped
resamples (Bickel and Freeman 1981), and so can be obtained by finding the shortest
interval URS-BTS = (L
∗, U∗) that satisfies
#(L∗≤L˜∗
k
<U˜∗
k
≤U∗)
K
≥ 1 − θ, and
#(L∗≤L˜∗
k
)
K
≃
#(U∗≥U˜∗
k
)
K
, where #() counts the number of statements that hold for k = 1, 2, . . . , K.
6 HERS Data: Treatment Effect Estimation and
Confounding Assessment
6.1 Preliminary Analyses
The upper panel of Table 3 summarizes the IPW estimate of the ATE and IV estimate
of the LATE of HAART on CD4 count. The IPW uses the variables listed in Table 1
as the measured confounders of V and assumes that e(V ; γ) = logit−1(γ⊤V ). The
IPW estimate of the ATE suggests that HAART can boost patient’s CD4 count by 27
cells/mm3 on average with a 95% confidence interval of (−16, 70). The IV estimate
of the LATE suggests that for those who would receive HAART at academic medical
centers but not at community clinics, HAART can increase CD4 count by 207 on
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average with a 95% CI of (−250, 664). In Table 3, we also list the “as-treated” (AT)
treatment effect, which is estimated by the contrast of the average CD4 counts between
those actually receiving HAART and those not. The difference between the IPW and
AT estimates can be regarded as the bias of AT estimate that is attributable to the
measured confounders.
6.2 Bounds on HAART Treatment Effect and Unmeasured
Confounding
For Assumption (A), we let the upper limits ξ0 = ξ1 = 500. (Recall that the two limits
are on the expected values of Y (0) among P11 and Y (1) among P00.) We choose the
two limits based on the facts that the average CD4 count at the previous visit was
much lower than 350 and at the eighth visit, the average CD4 count was 229 for those
treated and 216 for those untreated (refer to Tables 1). For Assumptions (B) and (B’),
we let δ11 = δ00 = δy0 = δtrt = 0, and further for (B’) let V be the variables listed
in Table 1. The lower panel of Table 3 summarizes the bounds estimates of the ATE
and τ . The bound estimate of the ATE (−196, 256) under (A) is not informative and
much wider than those under (B) (20, 231) and (B’) (18, 218). Assumption (B’) is not
necessarily stronger than (B), but by imposing observed data models and having the
estimated bounds smoothed over covariates, tighter bounds are resulted in. To obtain
uncertainty regions on these bound estimates, we draw K = 1, 000 bootstrap samples,
fixing the number of patients at the two types of study sites (academic medial centers
versus community clinics). Because the bounds estimates contain min() operation
which complicates the derivation of their standard errors, we use the K bootstrapped
samples to calculate the standard errors of the two ends of bound estimates. Table 3
summarizes the point-wise, strong, and bootstrap strong 95% coverage URs. The
difference between the 95% CI of the IPW estimate and 95% URs under (B) and (B’)
can be regarded as the bias of the IPW estimate due to unmeasured confounding. The
results suggest that unmeasured confounding tends to cause a downward bias and the
true ATE is likely to higher than what the IPW 95% CI suggests.
The bound estimates on τ under (B) and (B’) are (−204, 7.5) and (−191, 9.1), which
are much tighter and more informative than the bound estimate under (A) (−229, 223).
The 95% URs on τ are listed in Table 3. A possibly negative value of τ implies that
unmeasured factors resulted in preferential prescriptions of HAART to those with fewer
CD4 count in the HERS, and those on HAART might have up to 200 fewer CD4 count
(if left untreated) on average compared with those not on HAART.
6.3 Sensitivity to Unknown Parameters
In this section, we conduct a simple sensitivity analysis for the unknown parameters
used in the three sets of assumptions. We impose a common upper limit ξ = ξ0 = ξ1
for Assumption (A) and let ξ vary from 300 to 500. The bound estimates on the ATE
and τ along with bootstrap strong 95% URs are shown in Figure 1 (First row). For the
considered range, ξ has more influence on the upper (lower) bound estimate on ATE
14
Table 2: Estimated bounds on ATE and τ under Assumptions (A), (B) and (B’).
Parameter Estimated bound
(A) ATE [bˆ(ξ0, 0), bˆ(0, ξ1)]
τ [τˆn(bˆ(0, ξ1), γˆ), τˆn(bˆ(ξ0, 0), γˆ)]
(B) ATE [bˆ(cˆ0, µˆ00(0) + δ00), bˆ(0, cˆ1)]
τ [τˆn(bˆ(0, cˆ1), γˆ), τˆn(bˆ(cˆ0, µˆ00(0) + δ00), γˆ)]
(B’) ATE [πˆ01βˆIV +
∑
i
bˆv(cˆ0(Vi),cˆ2(Vi))
n
, πˆ01βˆIV +
∑
i
ubˆv(0,cˆ1(Vi))
n
]
τ [τˆn{πˆ01βˆIV +
∑
i
bˆv(0,cˆ1(Vi))
n
}, τˆn{πˆ01βˆIV +
∑
i
bˆv(cˆ0(Vi),cˆ2(Vi))
n
}]
Table 3: Estimates of HAART treatment effect on CD4 and τ . The 95% confidence
intervals (CI) for point estimates and 95% uncertainty regions for bound estimates
(URP-CAN, URS-CAN, and URS-BOOT; see Section 5.5) are shown in bold font. We
assume that ξ0 = ξ1 = 500 for (A); and that δ00 = δ11 = δy0 = δtrt = 0 for (B) and
(B’).
ATE τ
AT Point estimate 13 -
95% CI (−30, 56)
IPW Point estimate 27 -
95% CI (−16, 70)
IV Point estimate 207 -
95% CI (−250, 664)
Assumption:
(A): Bound estimate (−196, 256) (−229, 223)
95% URP-CAN (−229, 289) (−269, 266)
95% URS-CAN (−235, 295) (−277, 274)
95% URS-BTS (−233, 294) (−274, 273)
(B): Bound estimate (20, 231) (−204, 7.5)
95% URP-CAN (−9, 280) (−260, 49)
95% URS-CAN (−15, 289) (−271, 57)
95% URS-BTS (−14, 285) (−270, 57)
(B’): Bound estimate (18, 218) (−191, 9.1)
95% URP-CAN (−10, 261) (−234, 48)
95% URS-CAN (−16, 270) (−243, 56)
95% URS-BTS (−14, 270) (−243, 56)
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(on τ), and the resulting bound estimates remain wide and non-informative.
For (B) and (B’), we let δ00 (the lower limit of treatment effect among P00) rang
from −60 to 20 and fix δ11 = δy0 = δtrt = 0. (More sophisticated sensitivity analyses
that jointly evaluate δ11, δ00, δy0 and δtrt are possible.) We choose this range for
δ00 based on the magnitude of the AT and IPW estimates, and have it tilt toward
the negative side for the possibility that HAART could be harmful for those never
receiving HAART. Figure 1 (Second and third rows) shows that δ00 only affects the
lower (upper) bound estimates of the ATE (of τ). The ATE can be as high as over 200
cell/mm3, and the lower bound of ATE varies around zero depending on the value of
δ00. Again, a possible negative value of τ suggests that unmeasured confounding likely
causes HAART to be preferentially prescribed to those with poorer health.
7 Discussions
In the study of HERS, we propose to use an IV and sets of contextually plausible as-
sumptions to quantify the causal effect of a treatment as well as the degree of unmea-
sured confounding. We consider three sets of assumptions. Assumption (A) specifies
the limits of the expected unobservable potential outcomes, which leads to a simplified
version of the Robins-Manski bounds on ATE. Assumptions (B) and (B’) specify the
relative magnitudes between identified and unidentified potential outcome averages,
and lead to bounds that can be much tighter than (A). The 95% uncertainty regions
for the ATE under (B) and (B’) are more informative than the 95% CI of the IV
estimate, and have less concern of having unmeasured confounding bias compared to
the 95% CI of the IPW estimate. The bound estimates on the ATE and τ reveal that
unmeasured confounding could cause a downward bias on the ATE because of HAART
being preferentially prescribed to those with poorer health condition.
Quantifying the degree of unmeasured confounding can be valuable for analysis
of studies conducted in similar settings but having no IV. Several HIV observational
studies (e.g. Gange et al. 2007) have been conducted contemporarily as the HERS,
and could suffer from similar amount of unmeasured confounding. In those studies
when unmeasured confounding is of concern, analyses should be complemented with a
sensitivity analyses as described in Section 6.3. A plausible range for τ can be informed
from our study.
In this paper, we use the type of study site as an instrument variable, assuming
that two crucial IV assumptions (monotonicity and exclusion restriction) are satis-
fied. The observed HAART assignment rate at academic centers is higher than that at
community clinics. Such an observation suggests that the deterministic monotonicity
Pr(A1 ≥ A0) = 1 is plausible, but this assumption cannot be verified. As one limita-
tion of our study, this assumption will be violated if some individuals would receive
HAART at community clinics but not at academic medical centers. If the proportion
of these individuals (P10) is small, the bias due to the violation of the monotonicity
assumption is probably negligible. Alternatively, one can assume that P00 is absent,
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Figure 1: Sensitivities of bound estimates to ξ = ξ0 = ξ1 under Assumption (A); to
δ00 under Assumptions (B) and (B’). The gray zones show the bound estimates as a
function of ξ or δ00. The bootstrap strong 95% URS-BTS’s are shown as dashed lines.
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so that P11, P01 and P10 form a partition of the population. This assumption al-
lows everyone to have some chance of receiving HIV therapy, which is also sensible
for the HERS because these patients’ CD4 counts are less than 350 six months be-
fore, and allows for the possibility that some people would potentially be treated at a
community clinic but not an academic medical center. With this assumption, the pro-
portions of P11, P01 and P10 are identified because π01 = Pr(A = 0|Z = 0), Pr(P10) =
Pr(A = 0|Z = 1), and Pr(P11) = 1 − π01 − Pr(P10). The following estimands are also
identified: E{Y (0)|P01} = E(Y |A = 0, Z = 0), E{Y (0)|P10} = E(Y |A = 0, Z = 1),
E{Y (1)|P11orP01} = E(Y |A = 1, Z = 1), and E{Y (1)|P11orP10} = E(Y |A = 1, Z = 0).
A challenge here is how to incorporate the IV estimator, which now has an estimand as
a ‘weighted’ contrast of the average treatment effects between P01 and P10, to construct
constraint similar to (1). This may be worth further investigation.
Moreover, replacing the deterministic monotonicity with a stochastic monotonicity
assumption deserves explorations in the future. Roy et al. (2008) assumed Pr(A1 =
1|A0 = 1, V ) ≥ Pr(A1 = 1|A0 = 0, V ), and proposed to use auxiliary covariates to
estimate the memberships of principal strata. Small and Tan (2008) assumed Pr(A1 =
1|U) ≥ Pr(A0 = 1|U) with U being a latent variable satisfying certain conditions.
These stochastic monotonicity assumptions allow the possible presence of P10 and may
be more realistic in the HERS than the deterministic monotonicity.
The exclusion restriction could also be violated if the type of study site Z remains
associated with the outcome Y after accounting for the effect of Z on HAART receipt.
A weaker exclusion restriction assumption can be made, if the association between
the instrument and the outcome can be removed after conditioning on some measured
covariate V ∗, i.e. {Y (1), Y (0)} ⊥ Z|V ∗. In this case, the methods by Tan (2006) can
be implemented for identifying the LATE, and our method for bound estimation on
ATE and τ still applies.
There are several ways to account for the measured confounding. We use the method
of inverse probability weighting by specifying a propensity score model. Alternatively,
we can specify both an outcome regression model and a propensity score model and use
the doubly robust (DR) estimator (Bang and Robins 2005) to estimate the ATE. We do
not implement the DR estimator in this paper because when unmeasured confounding
exists the DR estimator is no longer guaranteed to be consistent for ATE and could
suffer more bias than other estimators. The simulations of Kang and Schafer (2007)
suggest that IPW is relatively robust to the impact of unmeasured confounding in term
of estimation bias. Because the focus issue of this paper is unmeasured confounding,
we use the IPW for estimating ATE.
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